INO 4212

Drug Profile

INO 4212

Alternative Names: GLS 5200; INO 4212 SynChon® Ebola immunotherapy; INO 4212 SynCon® vaccine; INO4212; VGX 4212

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inovio Pharmaceuticals
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 11 Apr 2017 Efficacy data from a phase I trial in Ebola virus infections released by Inovio
  • 11 Apr 2017 Pharmacodynamics data from a preclinical study in Ebola virus infections released by Inovio
  • 15 Mar 2017 Inovio Pharmaceuticals completes enrolment in an expansion study of the phase I trial for Ebola virus infection (In volunteers) in USA (NCT02464670; 9213076)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top